Retatrutide vs MOTS-c
Retatrutide and MOTS-c are both studied in metabolic research, but they represent opposite ends of the research-maturity spectrum — one a designed triple-receptor agonist with published Phase 3 efficacy data, the other a naturally-occurring mitochondrial peptide only just entering human trials in its own right.
At a Glance
| Retatrutide | MOTS-c | |
|---|---|---|
| Category | Weight Loss & Metabolic | Weight Loss & Metabolic |
| Molecular class | Synthetic triple agonist peptide (GIP/GLP-1/glucagon receptors) | 16-amino-acid peptide encoded within mitochondrial DNA |
| Origin | Eli Lilly incretin-biology group; preclinical paper Coskun et al., Cell Metabolism, Sept 2022 | Discovered 2015, USC (Lee et al.) |
| Studied via | Subcutaneous injection | Subcutaneous injection |
| Primary mechanism | Simultaneous activation of the GIP, GLP-1, and glucagon receptors | Activates AMPK / PGC-1α signaling |
| Primary research focus | Body weight loss, energy expenditure, glycemic control | Metabolic regulation, insulin sensitivity, exercise physiology |
| Human trial data | Phase 3 (TRIUMPH program) — up to 28.3% weight loss at 80 weeks (TRIUMPH-1); not yet approved | None for MOTS-c itself; an analog reached Phase 1b, and a Phase 2a trial of MOTS-c itself is underway |
How They Differ
Retatrutide is a deliberately engineered molecule from Eli Lilly's incretin-biology research group — the same program responsible for tirzepatide. It's designed to activate three separate hormone receptors (GIP, GLP-1, and glucagon) simultaneously, adding glucagon's energy-expenditure and hepatic lipid-oxidation effects on top of the two incretin pathways earlier compounds relied on. See its full discovery history, or how it compares to semaglutide and tirzepatide.
MOTS-c comes from an entirely different research tradition. Rather than being engineered from scratch, it was discovered in 2015 hidden inside the mitochondrial genome itself — a class of molecule identified only within the last decade. It's studied for activating AMPK and PGC-1α, the same signaling pathway aerobic exercise triggers in muscle tissue. See its full discovery history, or how it compares to 5-Amino-1MQ and SS-31.
Clinical Trial Data
Retatrutide: The Phase 3 TRIUMPH-1 trial (2,339 adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes) reported a mean weight loss of 28.3% at the 12mg dose over 80 weeks, with 45.3% of participants losing at least 30% of body weight — a threshold historically associated with bariatric surgery. A study extension in participants with baseline BMI ≥35 reached an average of 30.3% weight loss at 104 weeks. All three doses tested (4mg, 9mg, 12mg) met their primary and key secondary endpoints against placebo. Full peer-reviewed results are still pending publication, following the precedent set by Retatrutide's Phase 2 obesity data published in the New England Journal of Medicine in 2023. Retatrutide remains investigational and has not been approved by the FDA or any other regulator.
MOTS-c: MOTS-c itself has not completed a human clinical trial. CB4211, a novel analog of MOTS-c developed by CohBar (a related but distinct molecule, not MOTS-c itself), was tested in a Phase 1a/1b trial in 20 adults with obesity and elevated liver fat, meeting its primary safety endpoint with no serious adverse events and reducing the liver enzymes ALT (-25%) and AST (-17%) relative to placebo; CohBar's development of CB4211 was later discontinued for company reasons unrelated to the trial results. Separately, a Phase 2a trial of MOTS-c itself ("MOTS-MET," NCT07505745) is currently underway, testing whether 12 weeks of subcutaneous MOTS-c improves insulin sensitivity in 120 adults with prediabetes and overweight or obesity; results have not yet been posted.
Why They're Often Compared
Retatrutide and MOTS-c are two of KYIN's three Weight Loss & Metabolic compounds, and the comparison is really a study in contrasts rather than similarities. Retatrutide represents the mainstream, well-capitalized path of modern incretin-drug development — a designed molecule following directly in the footsteps of blockbuster approved drugs, already carrying strong published Phase 3 efficacy data. MOTS-c represents a newer and less-travelled research paradigm: an endogenous signaling peptide discovered by sequencing an overlooked genome, with human trial evidence that is only just beginning to accumulate. Researchers comparing the two are often weighing mechanism (receptor agonism vs. mitochondrial signaling) and evidence maturity as much as therapeutic category.
Retatrutide vs MOTS-c questions
Why are Retatrutide and MOTS-c often compared?
They're two of KYIN's three Weight Loss & Metabolic compounds, and they sit at very different points on the research-maturity spectrum — one a designed multi-receptor agonist deep into Phase 3 human trials, the other a naturally-occurring mitochondrial peptide still in earlier-stage human testing.
Which has stronger human trial data, Retatrutide or MOTS-c?
Retatrutide, by a wide margin. Its Phase 3 TRIUMPH-1 trial reported up to 28.3% mean weight loss at 80 weeks. MOTS-c itself has not completed a human trial — a related analog reached Phase 1b, and a Phase 2a trial of MOTS-c itself is currently underway with results not yet posted.
Are Retatrutide and MOTS-c studied together?
They're not sold as a combined blend, but both are frequently referenced together in body-composition and metabolic research given their shared Weight Loss / Metabolic category, despite acting through entirely different mechanisms.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.